RxDoctor Payments Data

Kerolos Abadeer Sedki Senada, MD

Gastroenterology · Orange Park, FLNPI 1376074286

Payments from drug & device makers

$3,599in general payments, 2019–2025

Across 174 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$394
  • Johnson & Johnson$324
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$192
  • Sanofi$166
  • Apollo Endosurgery US Inc$145
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,582100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,599 in reported general payments places this provider in the 50th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$165,728
Medicare patients
356
Services billed
2,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide15$7,980
SutabSod Sulf/Pot Chloride/Mag Sulf19$3,111
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl164$2,556
Mesalamine11$2,242
Esomeprazole Magnesium41$1,686
Dicyclomine Hcl70$1,252
Omeprazole136$1,197
Cholestyramine LightCholestyramine16$1,062
Lactulose34$745
Ondansetron OdtOndansetron16$728
Pantoprazole Sodium53$615
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl26$479
Famotidine34$321
LoperamideLoperamide Hcl16$235
Metronidazole12$140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,161$7,98015 claims
Braintree Laboratories, Inc.Sutab$26$3,11119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Orange Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →